Novo Nordisk A/S and Hims & Hers Health Inc. have resolved their bitter legal dispute and will partner to sell obesity medications on Hims' telehealth platform. The companies plan to announce the new agreement as early as Monday, according to a person familiar with the matter who requested anonymity. This comes after Novo abruptly ended a previous partnership last year when Hims refused to stop marketing copycat versions of its drugs.

The feud escalated in February when Novo sued Hims for allegedly breaching US patents on the ingredients in its best-selling medications Ozempic and Wegovy. Novo accused Hims of launching a copycat version of its new Wegovy weight-loss pill, with Novo's general counsel calling the move "egregious" at the time. The legal battle comes amid fierce competition in the obesity market, where Novo has been losing ground to rivals like Eli Lilly & Co.

Shares of Hims jumped 17% in after-hours trading following the news, though the stock had fallen 52% year-to-date through Friday's close. The partnership represents a surprising shift for Novo, which had been under mounting pressure to regain market share. The move suggests Novo is willing to work with telehealth platforms to expand access to its FDA-approved medicines, despite previous legal threats.